{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:54:26Z","timestamp":1773838466498,"version":"3.50.1"},"update-to":[{"DOI":"10.1002\/14651858.cd010457","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,11,14]],"date-time":"2014-11-14T00:00:00Z","timestamp":1415923200000}}],"reference-count":137,"publisher":"Wiley","issue":"11","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010457.pub2","type":"journal-article","created":{"date-parts":[[2014,11,13]],"date-time":"2014-11-13T22:57:23Z","timestamp":1415919443000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Uricosuric medications for chronic gout"],"prefix":"10.1002","volume":"2014","author":[{"given":"Alison SR","family":"Kydd","sequence":"first","affiliation":[{"name":"University of British Columbia; Division of Rheumatology; 1650 Terminal Ave, Suite 206 Nanaimo BC Canada V9S 0A3"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rakhi","family":"Seth","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust; Department of Rheumatology; Southampton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachelle","family":"Buchbinder","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine, Monash University; Monash Department of Clinical Epidemiology, Cabrini Hospital; Suite 41, Cabrini Medical Centre 183 Wattletree Road Malvern Victoria Australia 3144"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J","family":"Edwards","sequence":"additional","affiliation":[{"name":"University Hospital Southampton NHS Foundation Trust; Department of Rheumatology; Southampton UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Bombardier","sequence":"additional","affiliation":[{"name":"Institute for Work & Health; 481 University Avenue, Suite 800 Toronto ON Canada M5G 2E9"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,11,14]]},"reference":[{"key":"10.1002\/14651858.CD010457.pub2-BIB0001|cit1","unstructured":"Liang DR Xu N Zhang HM Cai YN Zhang HL Benzbromarone and probenecid in treating gout: a randomized controlled study West China Medical Journal 1994 405 8"},{"issue":"2","key":"10.1002\/14651858.CD010457.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00124743-199904000-00003","article-title":"Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study","volume":"5","author":"Perez-Ruiz","year":"1999","journal-title":"Journal of Clinical Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD010457.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1136\/ard.2008.091462","article-title":"A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg\/day versus benzbromarone 100-200 mg\/day in patients with gout","volume":"68","author":"Reinders","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD010457.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1136\/ard.2007.083071","article-title":"Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol","volume":"68","author":"Reinders","year":"2009","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"6 Suppl","key":"10.1002\/14651858.CD010457.pub2-BIB0005|cit5","first-page":"623","article-title":"Comparison of allopurinol and probenecid","volume":"25","author":"Scott","year":"1966","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"9","key":"10.1002\/14651858.CD010457.pub2-BIB0006|cit6","first-page":"1087","article-title":"The efficacy of combined low dose of allopurinol and benzbromarone compared to standard dose of allopurinol in hyperuricemia","volume":"87","author":"Akkasilpa","year":"2004","journal-title":"Journal of the Medical Association of Thailand"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0007|cit7","first-page":"2301","article-title":"Letter: a clinical impression of benzbromarone (Minuric)","volume":"48","author":"Allwright","year":"1974","journal-title":"South African Medical Journal"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0008|cit8","first-page":"98","article-title":"Zyloprim and other drugs in the management of gout","volume":"8","author":"Anonymous","year":"1966","journal-title":"Medical Letter on Drugs & Therapeutics"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1136\/dtb.6.26.102","article-title":"Ethebenecid (Urelim)","volume":"6","author":"Anonymous","year":"1968","journal-title":"Drug & Therapeutics Bulletin"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0010|cit10","first-page":"961","article-title":"Gout and the kidney","volume":"1","author":"Anonymous","year":"1968","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0011|cit11","first-page":"87","article-title":"Effect of long-term base therapy on the clinical picture of gout","volume":"53","author":"Baiatova","year":"1981","journal-title":"Terapevticheskii Arkhiv"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/bmj.1.5905.446","article-title":"Gout","volume":"1","author":"Bain","year":"1974","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0013|cit13","first-page":"40","article-title":"The use of Allomaron in treating hyperuricemia","volume":"66","author":"Balkarov","year":"1994","journal-title":"Terapevticheskii Arkhiv"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0014|cit14","first-page":"829","article-title":"Management of chronic and recurrent gout","volume":"8","author":"Ball","year":"1971","journal-title":"Modern Treatment"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0015|cit15","first-page":"957","article-title":"Antihyperuricemic drugs [in French]","volume":"110","author":"Bannwarth","year":"1988","journal-title":"Concours Medical"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0016|cit16","first-page":"40","article-title":"Gout","volume":"20","author":"Barden-Maja","year":"1999","journal-title":"Internal Medicine"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0017|cit17","first-page":"1336","article-title":"Allomaron in hyperuricemia and gout","volume":"55","author":"Barsom","year":"1979","journal-title":"Zeitschrift fur Allgemeinmedizin"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1136\/bmj.1.6179.1695","article-title":"Gout","volume":"1","author":"Bayliss","year":"1979","journal-title":"British Medical Journal"},{"issue":"6-7","key":"10.1002\/14651858.CD010457.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1080\/15257770802136032","article-title":"Determinants of the clinical outcomes of gout during the first year of urate-lowering therapy","volume":"27","author":"Becker","year":"2008","journal-title":"Nucleosides, Nucleotides and Nucleic Acids"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0020|cit20","first-page":"18","article-title":"Hyperuricemia: prevention of gout with drugs [in German]","volume":"151","author":"Bennack","year":"2006","journal-title":"Pharmazeutische Zeitung"},{"issue":"23","key":"10.1002\/14651858.CD010457.pub2-BIB0021|cit21","first-page":"719","article-title":"Effectiveness and tolerance of long-term uricosuric treatment","volume":"45","author":"Berg","year":"1990","journal-title":"Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete"},{"issue":"5683","key":"10.1002\/14651858.CD010457.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/bmj.4.5683.590","article-title":"Effect of drugs on urate binding to plasma proteins","volume":"4","author":"Bluestone","year":"1969","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/978-1-4615-9140-5_46","article-title":"Benzbromarone as a long-term uricosuric agent","volume":"122A","author":"Bluestone","year":"1980","journal-title":"Advances in Experimental Medicine & Biology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0024|cit24","first-page":"83","article-title":"Probenecid (Benemid); its uses and side-effects in 2,502 patients","volume":"95","author":"Boger","year":"1955","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0025|cit25","first-page":"23","article-title":"Diagnostic and therapeutic aids in gout and hyperuricemia","volume":"109","author":"Bollet","year":"1981","journal-title":"Medical Times"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0026|cit26","first-page":"342","article-title":"Normurat (benzbromaron) in the treatment of gout","volume":"38","author":"Bosmansky","year":"1979","journal-title":"Zeitschrift fur Rheumatologie"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0027|cit27","first-page":"165","article-title":"Evaluation of the therapy effects of Acidum tienilicum, benzbromaron and allopurinol in gout patients","volume":"4","author":"Bosmansky","year":"1982","journal-title":"Zeitschrift fur Rheumatologie"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0028|cit28","first-page":"283","article-title":"Results obtained with long-term benzbromarone therapy (author's translation)","volume":"86","author":"Bresnik","year":"1974","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0029|cit29","first-page":"546","article-title":"Long-term therapy with benzbromarone in uric arthritis","volume":"125","author":"Broll","year":"1975","journal-title":"Wiener Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0030|cit30","first-page":"287","article-title":"Effect of benziodarone and benzbromarone on the uric acid level in the blood and urine and on the incidence of gout attacks","volume":"18","author":"Brzozowska-Jurkowska","year":"1980","journal-title":"Reumatologia"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0031|cit31","first-page":"289","article-title":"Association of a uricosuric and a uric acid inhibitor in the prophylaxis and treatment of the basis of gout","volume":"117","author":"Carrasco","year":"1970","journal-title":"Revista Clinica Espanola"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0032|cit32","first-page":"291","article-title":"Results of long-term treatment of gout using Anturane","volume":"12","author":"Casademont","year":"1968","journal-title":"Revista Espanola de Reumatismo y Enfermedades Osteo-Articulares"},{"issue":"2","key":"10.1002\/14651858.CD010457.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10067-004-0978-4","article-title":"Elevated serum homocysteine levels for gouty patients","volume":"24","author":"Cheng","year":"2005","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/978-1-4757-1433-3_40","article-title":"Treatment of gout and hyperuricaemia by benzbromarone, ethyl 2 (dibromo-3,5 hydroxy-4 benzoyl)-3 benzofuran","volume":"41","author":"Gery","year":"1974","journal-title":"Advances in Experimental Medicine & Biology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0035|cit35","first-page":"443","article-title":"Treatment of gout with the combination of xanthine oxidase inhibitors and uricosuric agents","volume":"37","author":"Delbarre","year":"1970","journal-title":"Revue du Rhumatisme et des Maladies Osteo-Articulaires"},{"issue":"5","key":"10.1002\/14651858.CD010457.pub2-BIB0036|cit36","first-page":"296","article-title":"The effect on uric acid and other laboratory parameters. A long-term study","volume":"58","author":"Dorn","year":"1982","journal-title":"Zeitschrift fur Allgemeinmedizin"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"475","DOI":"10.5694\/j.1326-5377.1972.tb46879.x","article-title":"The management of gout","volume":"1","author":"Emmerson","year":"1972","journal-title":"Medical Journal of Australia"},{"issue":"1","key":"10.1002\/14651858.CD010457.pub2-BIB0038|cit38","first-page":"43","article-title":"Uricosuric activity of suxibuzone, a new phenylbutazone derivative","volume":"1","author":"Erill","year":"1975","journal-title":"Archivos de Farmacologia y Toxicologia"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0039|cit39","first-page":"5","article-title":"Analysis of the hypo-uricemic action of benzbromarone in 40 cases of gouty and non-gouty hyperuricemia","volume":"25","author":"Famaey","year":"1970","journal-title":"Journal Belge de Rhumatologie et de Medecine Physique"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/art.1780180731","article-title":"Uricosuric agents","volume":"18","author":"Fanelli","year":"1975","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/978-1-4615-9140-5_47","article-title":"The action of benzbromarone in relation to age, sex and accompanying diseases","volume":"122A","author":"Ferber","year":"1980","journal-title":"Advances in Experimental Medicine & Biology"},{"issue":"36","key":"10.1002\/14651858.CD010457.pub2-BIB0042|cit42","first-page":"3379","article-title":"Long-term treatment of hyperurikemia and gout; randomised study [in German]","volume":"37","author":"Frerick","year":"1987","journal-title":"Therapiewoche"},{"issue":"4","key":"10.1002\/14651858.CD010457.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/ard.33.4.298","article-title":"Gout and hyperlipidaemia","volume":"33","author":"Gibson","year":"1974","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/978-1-4615-2584-4_22","article-title":"Benzbromarone and fenofibrate are lipid lowering and uricosuric: a possible key to metabolic syndrome?","volume":"370","author":"Gresser","year":"1994","journal-title":"Advances in Experimental Medicine & Biology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0045|cit45","first-page":"176","article-title":"Pharmacotherapy of hyperuricaemia and gout [in German]","volume":"3","author":"Grobner","year":"1982","journal-title":"Aktuelle Endokrinologie und Stoffwechsel"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0046|cit46","first-page":"210","article-title":"Hyperuricemia and gout - treatment","volume":"127","author":"Grobner","year":"2002","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0047|cit47","first-page":"473","article-title":"On the influence of Anturan on uric acid and plasma lipids in patients with gout","volume":"80","author":"Gunther","year":"1968","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0048|cit48","first-page":"817","article-title":"Clinical findings and therapy of gout with special reference to the metabolic effects of sulfinpyrazone (Anturan) and allopurinol (Zyloric)","volume":"81","author":"Gunther","year":"1969","journal-title":"Wiener Klinische Wochenschrift"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0049|cit49","first-page":"52","article-title":"Gout and crystal arthropathy [in Spanish]","volume":"9","author":"Gutierrez","year":"1982","journal-title":"Investigacion Medica Internacional"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3810\/psm.2011.11.1946","article-title":"2011 recommendations for the diagnosis and management of gout and hyperuricemia","volume":"39","author":"Hamburger","year":"2011","journal-title":"Physician and Sportsmedicine"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3899\/jrheum.080768","article-title":"Gout in the elderly - a population health study","volume":"36","author":"Hanly","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0052|cit52","first-page":"S40","article-title":"Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients","volume":"85 Suppl 1","author":"Hanvivadhanakul","year":"2002","journal-title":"Journal of the Medical Association of Thailand"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0053|cit53","first-page":"55","article-title":"Treatment of gout and hyperuricemia","volume":"105","author":"Healey","year":"1977","journal-title":"Medical Times"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2165\/00003495-197714050-00002","article-title":"Benzbromarone: a review of its pharmacological properties and therapeutic use in gout and hyperuricaemia","volume":"14","author":"Heel","year":"1977","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0055|cit55","first-page":"241","article-title":"Probenecid-induced nephrotic syndrome","volume":"94","author":"Hertz","year":"1972","journal-title":"Archives of Pathology & Laboratory Medicine"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0056|cit56","first-page":"649","article-title":"Gout in advanced age","volume":"110","author":"Hollander","year":"1968","journal-title":"Munchener Medizinische Wochenschrift"},{"issue":"5","key":"10.1002\/14651858.CD010457.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/art.1780080455","article-title":"The effect of allopurinol (HPP) in the treatment of gout","volume":"8","author":"Houpt","year":"1965","journal-title":"Arthritis & Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD010457.pub2-BIB0058|cit58","first-page":"45","article-title":"Drug-induced hyperuricemia prevented by probenecid","volume":"2","author":"Hutchison","year":"1971","journal-title":"Journal of Medicine"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/art.1780170207","article-title":"Effect of single oral doses of benzbromarone on serum and urinary uric acid","volume":"17","author":"Jain","year":"1974","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0060|cit60","first-page":"651","article-title":"Benzbromarone withdrawn from the European market: another case of \"absence of evidence is evidence of absence\"?","volume":"22","author":"Jansen","year":"2004","journal-title":"Clinical & Experimental Rheumatology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Joseph-Ridge N Cazzetta S MacDonald P Clinical trials in crystal arthropathy Rheumatic Disease Clinics of North America 2006 359 82","DOI":"10.1016\/j.rdc.2006.02.002"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0062|cit62","first-page":"25","article-title":"Effect of decrease in hyperuricemia levels on joint, kidney and other symptoms in patients with gout","volume":"59","author":"Kawenoki-Minc","year":"1987","journal-title":"Terapevticheskii Arkhiv"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1136\/ard.25.Suppl_6.643","article-title":"Allopurinol in primary gout with and after the administration of uricosuric agents","volume":"25","author":"Kersley","year":"1966","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/ard.25.4.353","article-title":"Treatment of gout by reduction of uric acid production","volume":"25","author":"Kersley","year":"1966","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0065|cit65","first-page":"199","article-title":"The pharmaceutical treatment of gout","volume":"8","author":"Kersley","year":"1966","journal-title":"Annals of Physical Medicine"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1136\/ard.29.1.89","article-title":"Long-term use of allopurinol in the treatment of gout","volume":"29","author":"Kersley","year":"1970","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1177\/00369330730180S106","article-title":"The treatment of gout","volume":"18 Suppl 1","author":"Kersley","year":"1973","journal-title":"Scottish Medical Journal"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0068|cit68","doi-asserted-by":"crossref","unstructured":"Kim KY Schumacher HR Hunsche E Wertheimer AI Kong SX A literature review of the epidemiology and treatment of acute gout Clinical Therapeutics 2003 1593 617","DOI":"10.1016\/S0149-2918(03)80158-3"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0069|cit69","first-page":"455","article-title":"Allopurinol in the treatment of gout","volume":"27","author":"Klein","year":"1968","journal-title":"Zeitschrift fur Rheumaforschung"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0070|cit70","first-page":"1014","article-title":"On clinical experiences with 2-ethyl-3(4-hydroxy-3,5-dibrombenzoyl)-benzofuran (\"Benzbromaron\") in the therapy of gout and hyperuricemia","volume":"118","author":"Kotzaurek","year":"1968","journal-title":"Wiener Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1136\/ard.25.Suppl_6.634","article-title":"Treatment of gout with allopurinol and sulphinpyrazone in combination and with allopurinol alone","volume":"25","author":"Kuzell","year":"1966","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Safety"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0073|cit73","first-page":"369","article-title":"A new drug therapy for gout and hyperuricemia. Long term results","volume":"52","author":"Masbernard","year":"1976","journal-title":"Therapeutique"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0074|cit74","first-page":"1117","article-title":"Drug-induced hepatic injury, the challenge for cause investigation","volume":"59","author":"Matsumoto","year":"2011","journal-title":"Rinsho Byori - Japanese Journal of Clinical Pathology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0075|cit75","first-page":"953","article-title":"Therapy of hyperuricemia and gout. Effect of a combination therapy of allopurinol with benzbromarone","volume":"101","author":"Matzkies","year":"1983","journal-title":"Fortschritte der Medizin"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0076|cit76","first-page":"491","article-title":"Changes in the serum concentration of uric acid under the effect of benzbromaronum","volume":"111","author":"Mertz","year":"1969","journal-title":"Munchener Medizinische Wochenschrift"},{"issue":"35","key":"10.1002\/14651858.CD010457.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1055\/s-0028-1104258","article-title":"Reducing the risks in the treatment of gout and hyperuricaemia (author's translation)","volume":"101","author":"Mertz","year":"1976","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"15","key":"10.1002\/14651858.CD010457.pub2-BIB0078|cit78","first-page":"664","article-title":"Therapy with allopurinol and benzbromarone, single and combined. Renal elimination of lithogenous and colloid protective substances (author's translation)","volume":"72","author":"Mertz","year":"1977","journal-title":"Medizinische Klinik"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1055\/s-0028-1105471","article-title":"Isolated or combined drug therapy of hyperuricemia?","volume":"102","author":"Mertz","year":"1977","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"36","key":"10.1002\/14651858.CD010457.pub2-BIB0080|cit80","first-page":"974","article-title":"Excretion and serum concentrations of allopurinol, oxipurinol and oxipurines in combined treatment with allopurinol and benzbromarone in increasing doses","volume":"34","author":"Mertz","year":"1983","journal-title":"Medizinische Welt"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0081|cit81","first-page":"851","article-title":"Current therapy: combined drug therapy of hyperuricemia, gout and alcohol induced fatty liver","volume":"101","author":"Mertz","year":"1983","journal-title":"Fortschritte der Medizin"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/archinte.1966.00290150038008","article-title":"The effects of allopurinol on serum and urinary uric acid","volume":"118","author":"Mikkelsen","year":"1966","journal-title":"Archives of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010457.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00315283","article-title":"The effect of benzbromarone on allopurinol\/oxypurinol kinetics in patients with gout","volume":"44","author":"M\u00fcller","year":"1993","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD010457.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00315283","article-title":"The effect of benzbromarone on allopurinol\/oxypurinol kinetics in patients with gout","volume":"44","author":"M\u00fcller","year":"1993","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/rheumatology\/17.3.143","article-title":"Treatment of gout with alternate-day hypo-uricaemic drugs","volume":"17","author":"Nishizawa","year":"1978","journal-title":"Rheumatology & Rehabilitation"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0086|cit86","first-page":"253","article-title":"Treatment of the gouty diathesis with a xanthine oxidase inhibitor. A clinical trial of allopurinol","volume":"129","author":"Nyfos","year":"1967","journal-title":"Ugeskrift for Laeger"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/imj.1968.17.3.242","article-title":"A short trial assessment of uricosuric therapy in gout","volume":"17","author":"Palmer","year":"1968","journal-title":"Australasian Annals of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010457.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/cpt1979262205","article-title":"Ticrynafen and probenecid in hyperuricemic, hypertensive men","volume":"26","author":"Peitzman","year":"1979","journal-title":"Clinical Pharmacology & Therapeutics"},{"issue":"9","key":"10.1002\/14651858.CD010457.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1002\/acr.20221","article-title":"Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout","volume":"62","author":"Perez-Ruiz","year":"2010","journal-title":"Arthritis care & research"},{"issue":"4","key":"10.1002\/14651858.CD010457.pub2-BIB0090|cit90","first-page":"361","article-title":"Effect of benziodarone on the renal excretion of uric acid","volume":"12","author":"Podevin","year":"1967","journal-title":"Revue Francaise d Etudes Cliniques et Biologiques"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0091|cit91","first-page":"2555","article-title":"Benemid in the treatment of primary and secondary gout","volume":"45","author":"Rausch-Stroomann","year":"1965","journal-title":"Medizinische Welt"},{"issue":"9","key":"10.1002\/14651858.CD010457.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-006-0528-3","article-title":"Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients","volume":"26","author":"Reinders","year":"2007","journal-title":"Clinical Rheumatology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0093|cit93","first-page":"209","article-title":"Probenecid (B enemid) in the treatment of gout and gouty arthritis","volume":"42","author":"Rice","year":"1959","journal-title":"Minnesota Medicine"},{"issue":"5509","key":"10.1002\/14651858.CD010457.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1136\/bmj.2.5509.321","article-title":"Allopurinol in treatment of gout","volume":"2","author":"Scott","year":"1966","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.27.3.249","article-title":"Probenecid, nephrotic syndrome, and renal failure","volume":"27","author":"Scott","year":"1968","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0096|cit96","first-page":"411","article-title":"Allopurinol in the treatment of gout","volume":"87","author":"Seebach","year":"1967","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0097|cit97","first-page":"3295","article-title":"Uric acid inhibitors in the treatment of gout. Apropos of 126 cases [in French]","volume":"46","author":"Serre","year":"1970","journal-title":"La Semaine des Hopitaux"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/ard.25.Suppl_6.688","article-title":"Allopurinol therapy of gout with renal complications","volume":"25","author":"Sjoberg","year":"1966","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/17843286.1967.11716655","article-title":"Hypouricemizing effect of benzbromarone. Study of 24 cases (preliminary results)","volume":"22","author":"Sternon","year":"1967","journal-title":"Acta Clinica Belgica"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1093\/rheumatology\/kel071","article-title":"Effectiveness of interventions for the treatment of acute and prevention of recurrent gout - a systematic review","volume":"45","author":"Sutaria","year":"2006","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0101|cit101","first-page":"155","article-title":"The efficacy of treatment with allopurinol versus uricosuric drugs in gout","volume":"20","author":"Weinberger","year":"1978","journal-title":"Panminerva Medica"},{"issue":"4","key":"10.1002\/14651858.CD010457.pub2-BIB0102|cit102","first-page":"183","article-title":"Monosodium urate deposition arthropathy part II: treatment and long-term management of patients with gout","volume":"5","author":"Wortmann","year":"2005","journal-title":"Advanced Studies in Medicine"},{"issue":"12","key":"10.1002\/14651858.CD010457.pub2-BIB0103|cit103","first-page":"898","article-title":"Study on mechanisms of electroacupuncture treatment of acute gouty arthritis","volume":"27","author":"Xie","year":"2007","journal-title":"Zhongguo Zhenjiu"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1016\/S0026-0495(97)90151-7","article-title":"Effect of allopurinol and benzbromarone on the concentration of uridine in plasma","volume":"46","author":"Yamamoto","year":"1997","journal-title":"Metabolism: Clinical & Experimental"},{"issue":"11","key":"10.1002\/14651858.CD010457.pub2-BIB0105|cit105","first-page":"1731","article-title":"Uricosuric Effect of Yagifraxin Tablet in Gout: Comparison with Sulfinpyrazone","volume":"5","author":"Yonetsugu","year":"1971","journal-title":"Clinical Report: Kiso to Rinsho"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)","volume":"65","author":"Zhang","year":"2006","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0107|cit107","first-page":"2405","article-title":"Effect of benzbromarone on serum uric acid level and uric acid excretion of patients with gout","volume":"95","author":"Zollner","year":"1970","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"3","key":"10.1002\/14651858.CD010457.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study","volume":"82","author":"Campion","year":"1987","journal-title":"American Journal of Medicine"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0109|cit109","unstructured":"Cates C Visual Rx Version 3 www.nntonline.net\/visualrx\/"},{"issue":"4","key":"10.1002\/14651858.CD010457.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1136\/ard.2010.139899","article-title":"Methods of tophus assessment in clinical trials of chronic gout: a systematic literature review and pictorial reference guide","volume":"70","author":"Dalbeth","year":"2011","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD010457.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/jama.292.11.1363","article-title":"Clinical trial registration: a statement from the International Committee of Medical Journal Editors","volume":"292","author":"DeAngelis","year":"2004","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0112|cit112","unstructured":"Deeks JJ Higgins JPT Altman DG Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD010457.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1681\/ASN.2006040415","article-title":"Human renal organic anion transporter 4 operates as an asymmetric urate transporter","volume":"18","author":"Hagos","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD010457.pub2-BIB0114|cit114","first-page":"25","article-title":"Severe hepatotoxicity related to benzarone: a report of three cases with two fatalities","volume":"15","author":"Hautekeete","year":"1995","journal-title":"Liver (Copenhagen)"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0115|cit115","unstructured":"Higgins JPT Altman DG Sterne JAC Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0116|cit116","unstructured":"Higgins JPT Deeks JJ Altman DG Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0117|cit117","unstructured":"Higgins JPT Deeks JJ Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0118|cit118","first-page":"1445","article-title":"Clinical gout and the pathogenesis of hyperuricemia","volume-title":"Arthritis and Allied Conditions","author":"Holmes","year":"1985"},{"issue":"7","key":"10.1002\/14651858.CD010457.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1093\/rheumatology\/ker023","article-title":"Minimally important differences of the gout impact scale in a randomized controlled trial","volume":"50","author":"Khanna","year":"2011","journal-title":"Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD010457.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care & Research"},{"issue":"4","key":"10.1002\/14651858.CD010457.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/art.10511","article-title":"Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout","volume":"47","author":"Perez-Ruiz","year":"2002","journal-title":"Arthritis & Rheumatism"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0122|cit122","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2011"},{"issue":"10","key":"10.1002\/14651858.CD010457.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3899\/jrheum.090370","article-title":"Outcome domains for studies of acute and chronic gout","volume":"36","author":"Schumacher","year":"2009","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0124|cit124","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0125|cit125","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD010457.pub2-BIB0126|cit126","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006077.pub2","article-title":"Allopurinol for chronic gout","author":"Seth","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010457.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1440-1797.2010.01368.x","article-title":"Interactions of urate transporter URAT1 in human kidney with uricosuric drugs","volume":"16","author":"Shin","year":"2011","journal-title":"Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD010457.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis & Rheumatism"},{"issue":"7","key":"10.1002\/14651858.CD010457.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.3899\/jrheum.110271","article-title":"Patient-reported outcomes in chronic gout: a report from OMERACT 10","volume":"38","author":"Singh","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD010457.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.berh.2010.10.004","article-title":"Epidemiology of gout: an update","volume":"24","author":"Smith","year":"2010","journal-title":"Best Practice Research in Clinical Rheumatology"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0131|cit131","unstructured":"Sterne JAC Egger M Moher D Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD010457.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2165\/00003088-200847020-00004","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects","volume":"47","author":"Stocker","year":"2008","journal-title":"Clinical Pharmacokinetics"},{"issue":"5","key":"10.1002\/14651858.CD010457.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3899\/jrheum.101160","article-title":"Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout","volume":"38","author":"Stocker","year":"2011","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD010457.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/ard.62.6.572","article-title":"Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and\/or losartan on uric acid metabolism","volume":"62","author":"Takahashi","year":"2003","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"11","key":"10.1002\/14651858.CD010457.pub2-BIB0135|cit135","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008653.pub2","article-title":"Febuxostat for treating chronic gout","author":"Tayar","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010457.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis & Rheumatism"},{"issue":"10","key":"10.1002\/14651858.CD010457.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis & Rheumatism"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010457.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T15:46:10Z","timestamp":1721663170000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010457.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Musculoskeletal Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,11,14]]},"references-count":137,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2014,11]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010457.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,14]]}}}